ENXTPA:BIM
ENXTPA:BIMMedical Equipment

Is bioMérieux Still Worth Watching After Recent 8.6% Dip in 2025?

So, you are considering what’s next for bioMérieux stock and wondering if this is the right moment to act. Maybe you have watched the prices ebb and flow lately, or maybe you are just tuning in. Either way, you are not alone, as investors everywhere are weighing the signals and asking if now is a smart entry, a time to hold, or a reason to steer clear. The stock’s journey has been, to put it mildly, eventful. In the past week, prices slipped by 2.7%, and over the last month, they have dropped...
ENXTPA:GET
ENXTPA:GETInfrastructure

How Does Getlink Stack Up After Recent Cross-Channel Transport Agreement?

If you’re wrestling with what to do next on Getlink, you’re not alone. The company’s share price has certainly kept investors on their toes lately. Over the last week, the stock edged up by 1.2%, hinting at fresh optimism. Zoom out a bit further, and the picture gets choppier. A dip of nearly 6% in the past month was followed by a modest 1.6% gain year-to-date, and, for the long-haulers, a 47.3% return over five years. These figures reflect both the volatility and potential that come with...
ENXTPA:EXA
ENXTPA:EXAAerospace & Defense

Exail Technologies (ENXTPA:EXA) Reports 47% Price Increase Over The Last Quarter

Exail Technologies (ENXTPA:EXA) recently achieved a significant milestone with the first sale of its DriX H-9 autonomous surface drone to a global hydrographic authority for naval defense, enhancing its foothold in the USV market. This came alongside a major European navy's order for five DriX H-8 drones. These developments, along with the confirmed expectation of double-digit revenue growth for 2025, likely bolstered market sentiment, aligning with the overall market's strong performance and...
ENXTPA:NRO
ENXTPA:NROIT

Neurones (ENXTPA:NRO) Half-Year Sales Surpass €424M But Net Income Declines

Neurones (ENXTPA:NRO) reported its half-year earnings, showing an increase in sales to EUR 424 million but a decline in net income to EUR 23 million. Despite these mixed results, the company's share price rose 3.8% last week. This movement coincides with broader market trends, as major stock indexes, including the Dow Jones and S&P 500, experienced record highs amid anticipation of interest rate cuts by the Federal Reserve. While the sales growth from Neurones supports the broader positive...
ENXTPA:RCO
ENXTPA:RCOBeverage

Rémy Cointreau (ENXTPA:RCO) Revises Earnings Guidance for FY 2025-26

Rémy Cointreau (ENXTPA:RCO) recently revised its earnings guidance for fiscal year 2025-26, lowering its expectations while still targeting mid-single-digit organic sales growth, driven by a rebound in U.S. sales. Despite this, the company's share price declined 8% over the last quarter. The downward guidance and adjustments in expected tariff impacts likely weighed on investor sentiment. Additionally, a dividend decrease and changes in the board composition, although important for...
ENXTPA:XFAB
ENXTPA:XFABSemiconductor

X-FAB Silicon Foundries (ENXTPA:XFAB) Reaffirms 2025 Revenue Outlook of US$840M to US$870M

X-FAB Silicon Foundries (ENXTPA:XFAB) reiterated its earnings guidance for 2025, maintaining revenue expectations between USD 840 million and USD 870 million, highlighting its aim for high single-digit growth. Over the last quarter, the company's share price gained 11%, which could be attributed to its updated financial guidance in July and consistent revenue projections despite reporting a second-quarter net loss of USD 0.4 million. This performance took place against a backdrop of robust...